Udayan Guha's departure as Chief Medical Officer of NextCure, Inc. was reported, effective October 31, 2026; the filing names no successor. As of November 6, 2026, NextCure, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 30, 2026, naming 1 departure (Form 8-K, October 30, 2026).
NextCure, Inc. announced the departure of its Chief Medical Officer on Oct 30. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like NextCure, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
NextCure, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-30. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as NextCure, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-07-14 (layoff filings and notices).
Also on the record for NextCure, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 20, 2026 | Stake report, Schedule 13G, by JP Sailing Capital Ltd | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by ADAR1 Capital Management, LLC | 15.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Ikarian Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Squadron Master Fund LP | 1.6% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Affinity Asset Advisors, LLC | 6.4% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G, by Adage Capital Management, L.P. | 7.67% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by SilverArc Capital Management, LLC | 4.9% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by Simcere Zaiming, Inc. | 9.4% of the class | 5%+ stakes | Source |
| March 5, 2026 | Stake report, Schedule 13D/A, by Sofinnova Venture Partners IX, L.P. ("SVP IX") | 7.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Ikarian Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Squadron Master Fund LP | 9.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Pfizer Inc. (IRS Identification No.: 13-5315170) | 3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs NextCure, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on NextCure, Inc. and the records around it.
NextCure, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Layoff notices Jul 2026
- Form D filing Dec 2025
- Who owns it
Companies that share a holder
- Sofinnova Venture Partners IX, L.P. ("SVP IX") also filed stake reports on 1 other company: ArriVent Biopharma, Inc. (Mar 2026)
- Pfizer Inc. (IRS Identification No.: 13-5315170) also filed stake reports on 4 other companies: TREX BIO, INC. (Oct 2026), ORIC Pharmaceuticals, Inc. (May 2026), Allogene Therapeutics, Inc. (Feb 2026)
- SilverArc Capital Management, LLC also filed stake reports on 8 other companies: Cellectar Biosciences Inc (Aug 2026), ELUTIA INC. (Aug 2026), TELA BIO, INC. (Aug 2026)
Watch NextCure, Inc.
Get an email when NextCure, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on NextCure, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on NextCure, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NextCure, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 18 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-30 | Out | Chief Medical Officer | 2026-10-31 | 8-K, 2026-10-30 |
Who leads NextCure, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Udayan Guha, departure reported, effective 2026-10-31 (filed 2026-10-30). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on NextCure, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Medical Officer at NextCure, Inc., with the record behind each one.
Find candidates like Chief Medical Officer at NextCure, Inc.Every change, in the filing's words
Departing: Udayan Guha, Chief Medical Officer, effective 2026-10-31
On October 26, 2026 NextCure, Inc. (the "Company") determined that the employment of Dr. Udayan Guha, M.D., Ph.D., Chief Medical Officer and a named executive officer of the Company, will be terminated effective October 31, 2026, in contemplation of the pending merger of the Company and Avere Therapeutics, Inc (the "Merger").
- In connection with his departure, Dr. Guha entered into a severance agreement and release with the Company (the "Severance Agreement").
- In exchange for a release of claims in favor of the Company, the Severance Agreement provides for severance benefits consistent with those provided for a termination without cause under Dr. Guha's existing employment agreement, as described in the Company's Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 24, 2026 (the "Employment Agreement").
- Subject to and conditioned upon the occurrence of the closing of the Merger, the Severance Agreement provides for additional severance equal to the enhanced severance benefits for a termination without cause in relation to a change in control, as set forth in Dr. Guha's Employment Agreement.
- The Company and its Board of Directors thank Dr. Guha for his leadership at the Company and are grateful for his many valuable contributions during his tenure.
Tools for this story
Each opens in a new tab, filled in for NextCure, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.